SELECT Brentuximab Vedotin TRIAL

ECHELON-3

SGN35-015

SGN35-025

SGN35-027

SGN35-028

SGN35-032

SGN35-033

CHECKMATE 436

CHECKMATE 744

SELECT Enfortumab Vedotin TRIAL

EV-304

EV-303

EV-302

EV-202

EV-103

EV-104

SELECT Tucatinib TRIAL

HER2CLIMB-02

HER2CLIMB-05

COMPASSHER2-RD

HER2CLIMB-04

SGNTUC-019

MOUNTAINEER

MOUNTAINEER-02

SGNTUC-024

SELECT Tisotumab Vedotin TRIAL

innovaTV 301

innovaTV 204

innovaTV 205

innovaTV 206

innovaTV 207

innovaTV 208

SELECT Ladiratuzumab Vedotin TRIAL

SGNLVA-005

SGNLVA-002

SGNLVA-001

SELECT SEA-CD40 TRIAL

SGNS40-002

SGNS40-001

PUBLICATIONS

Click here to learn more about our publications at this congress.

Corporate Sponsored Presentations

Abstract #/Title/Lead Author

Type/Session Category & Title

Session Time & Location

7528 / Brentuximab Vedotin ECHELON-1

Brentuximab vedotin with Chemotherapy in Adolescents and Young Adults (AYAs) with Stage III or IV Hodgkin Lymphoma: a Subgroup Analysis From the Phase 3 ECHELON-1 Study

Lead Author: H. Crosswell

Poster Presentation

Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia

Friday, June 4, 2021

On demand, 9:00 am ET

TPS7571 / Brentuximab Vedotin SGN35-031 TIP

Brentuximab vedotin in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (SGN35-031, Trial in Progress)

Lead Author: N. Bartlett

Poster Presentation

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Friday, June 4, 2021

On demand, 9:00 am ET

4528 / Enfortumab Vedotin EV-103 Cohort A

Study EV-103: Update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC)

Lead Author: T. Friedlander

Poster Presentation

Genitourinary Cancer—Kidney and Bladder

Friday, June 4, 2021

On demand, 9:00 am ET

4524 / Enfortumab Vedotin EV-201 Cohort 2

Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors: An updated analysis of EV-201 Cohort

Lead Author: B. McGregor

Poster Presentation

Genitourinary Cancer—Kidney and Bladder

Friday, June 4, 2021

On demand, 9:00 am ET

4539 / Enfortumab Vedotin EV-301

Quality of Life, Functioning, and Symptoms in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma From EV-301: A Randomized Phase 3 Trial of Enfortumab Vedotin vs Chemotherapy

Lead Author: R. Mamtani

Poster Presentation

Genitourinary Cancer—Kidney and Bladder

Friday, June 4, 2021

On demand, 9:00 am ET

TPS4587 / Enfortumab Vedotin EV-304 TIP

KEYNOTE-B15/EV-304: randomized phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC) (Trial in Progress)

Lead Author: C. Hoimes

Poster Presentation

Friday, June 4, 2021

On demand, 9:00 am ET

1043 / Tucatinib HER2CLIMB

Updated Results of Tucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Pretreated HER2+ Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB)

Lead Author: G. Curigliano

Poster Presentation

Breast Cancer—Metastatic

Friday, June 4, 2021

On demand, 9:00 am ET

TPS315 / Tucatinib SGNTUC-019 TIP

SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations (Trial in Progress)

Lead Author: T. Stinchcombe

Poster Presentation

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Friday, June 4, 2021

On demand, 9:00 am ET

TPS1097 / Tucatinib HER2CLIMB-04 TIP

HER2CLIMB-04: Phase 2 open label trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ unresectable locally-advanced or metastatic breast cancer with and without brain metastases (HER2CLIMB-04, Trial in Progress)

Lead Author: I. Krop

Poster Presentation

Breast Cancer – Metastatic

Friday, June 4, 2021

On demand, 9:00 am ET

1044 / Tucatinib 380-IST-004

Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer

Lead Author: E. Stringor-Reasor

Poster Presentation

Breast Cancer – Metastatic

Friday, June 4, 2021

On demand, 9:00 am ET

TPS595 / Tucatinib CompassHER2 RD TIP

A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + Tucatinib/Placebo in Patients with Residual HER2-Positive Invasive Breast Cancer (Trial In Progress)

Lead Author: C. O’Sullivan

Poster Presentation

Breast Cancer—Local/Regional/Adjuvant

Friday, June 4, 2021

On demand, 9:00 am ET

TPS5596 / Tisotumab Vedotin innovaTV 301 TIP

Tisotumab Vedotin vs Investigator’s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer (innovaTV 301/ENGOT cx12/GOG 3057, Trial in Progress)

Lead Author: I. Vergote

Poster Presentation

Gynecologic Cancer

Friday, June 4, 2021

On demand, 9:00 am ET

TPS3144 / SGN-B6A SGNB6A-001 TIP

A Phase 1 Study of SGN-B6A, an Antibody-Drug Conjugate Targeting Integrin Beta-6, in Patients With Advanced Solid Tumors (SGNB6A-001, Trial in Progress)

Lead Author: A. Patnaik

Poster Presentation

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Friday, June 4, 2021

On demand, 9:00 am ET

TPS2657 / SEA-TGT SGNTGT-001 TIP

SGNTGT-001: A Phase 1 Study of SEATGT, an Effector-Function Enhanced Monoclonal Antibody (mAb), in Advanced Malignancies (Trial in Progress)

Lead Author: E. Garralda

Poster Presentation

Developmental Therapeutics—Immunotherapy

Friday, June 4, 2021

On demand, 9:00 am ET

USM/COR/2021/0017

What would you like to do?

Medical Information

Clinical Trials

Pipeline

Videos

Welcome to the Seagen Medical Affairs website!

Instructions

Please fill out the form to send us any questions or feedback

How was your experience on the Seagen Medical Affairs website?

PUBLICATIONS

Corporate Sponsored Presentations

What would you like to do?